What happens when the evidence is incomplete, the terminology changes and the old follow-up habits no longer fit? In Part 2 of this thoughtful conversation, Dr. Julie Ann Sosa takes listeners into the gray zones of the 2025 ATA guidelines, from pathology and posterior tumors to surveillance limits and the future of decision support. It is a engaging conversation about where thyroid cancer care is becoming more precise and where the field still has hard questions to answer.
Categories
English 
Español de México